

is

(FILE 'HOME' ENTERED AT 17:35:09 ON 30 OCT 2001)

FILE 'BIOSIS' ENTERED AT 17:35:46 ON 30 OCT 2001

L1 0 S ALA DEFICIENCY PORPHYRIA TREATMENT
L2 0 S TRATMENT ALA DEFICIENCY PORPHYRIA
L3 0 S PORPHYRIAS TREATMENT (W) ENZYMES
L4 1 S PORPHYRIAS TREATMENT
L5 1 S PORPHYRIA CUTANEA TARDA (W)TREATMENT
L6 0 S HEREDITARY COPROPORPHYRIA (W) TREATMENT
L7 0 S TREATMENT (W) COPROPORPHYRINOGEN OXIDASE
L8 0 S COPROPORPHYRINOGEN ADMINISTRATION
L9 0 S UROPORPHYRINOGEN DECARBOXYLASE ADMINISTRATION
L10 0 S UROPORPHYRINOGEN DECARBOXYLASE (A)ADMINISTRATION
L11 0 S COPROPORPHYRINOGEN OXIDASE (A) ADMINISTRATION
L12 0 S PROTOPORPHYRINOGEN OXIDASE (A) ADMINISTRATION
L13 0 S UROPORPHYRINOGEN III SYNTHASE (A) ADMINISTRATION
L14 0 S UROPORPHYRINOGEN DECARBOXYLASE (A) ADMINISTRATION
L15 450 S UROPORPHYRINOGEN DECARBOXYLASE
L16 1 S L15 AND CLINICAL APPLICATION
L17 0 S PORPHOBILINOGEN DEAMINASE (A) CLINICAL APPLICATION

FILE 'STNGUIDE' ENTERED AT 17:53:44 ON 30 OCT 2001

L18 0 S ALA DEHYDRATASE (A)CLINICAL APPLICATION
L19 0 S UROPORPHYRINOGEN OXIDASE (A) CLINICAL APPLICATION
L20 0 S COPROPORPHYRINOGEN OXIDASE
L21 0 S UROPORPHYRINOGEN III SYNTHASE (A) CLINICAL APPLICATION
L22 0 S CLINICAL APPLICATION (A) FERROCHELATASE

FILE 'CAPLUS' ENTERED AT 17:59:26 ON 30 OCT 2001

L23 0 S L1
L24 0 S L2
L25 0 S L3
L26 1 S L4
L27 4 S L5
L28 4 S L5
L29 0 S L6
L30 0 S L7
L31 0 S L8
L32 0 S L9
L33 0 S L10
L34 0 S L11
L35 0 S L12
L36 0 S L13
L37 0 S L14
L38 359 S L15
L39 0 S CLINICAL APPLICATION (A)L38
L40 0 S L38 (A) TREATMENT
L41 359 S L15
L42 0 S L16
L43 0 S L17
L44 0 S PORPHOBILINOGEN DEAMINASE (A) ADMINISTRATION
L45 0 S PORPHOBILINOGEN DEAMINASE (A)CLINICAL APPLICATION
ADMINISTRAT
L46 0 S PORPHOBILINOGEN DEAMINASE (A)CLINICAL APPLICATION
L47 0 S PORPHOBILINOGEN DEAMINASE (A) PHARMACEUTIC USE
L48 0 S PORPHOBILINOGEN DEAMINASE (A) PHARMACEUTICAL COMPOSITION
USE
L49 0 S PORPHOBILINOGEN DEAMINASE (A) PHARMACEUTICAL COMPOSITION

L50 0 S L18
L51 0 S PORPHOBILINOGEN DEAMINASE (A) PHARMACEUTICAL USE
L52 0 S PORPHOBILINOGEN DEAMINASE (A) TREATMENT
L53 0 S PORPHOBILINOGEN DEAMINASE (A) ADMINISTRATION
L54 0 S PORPHOBILINOGEN DEAMINASE (A) PHARMACEUTICAL COMPOSITION
L55 0 S TREATMENT (W)PORPHOBILINOGEN DEAMINASE

FILE 'USPATFULL' ENTERED AT 18:13:34 ON 30 OCT 2001

L56 0 S L1
L57 0 S L54
L58 0 S PORPHOBILINOGEN DEAMINASE (A)CLINICAL APPLICATION
L59 0 S L55

FILE 'EUROPATFULL' ENTERED AT 18:15:41 ON 30 OCT 2001

L60 0 S L44
L61 0 S L45
L62 0 S L46
L63 0 S L47
L64 0 S L48
L65 0 S L49
L66 0 S L50
L67 0 S L51
L68 0 S L52
L69 0 S L53
L70 0 S L54
L71 0 S L55

=>

d 11 300 bib

L1 ANSWER 300 OF 441 MEDLINE
AN 91346824 MEDLINE
DN 91346824 PubMed ID: 1878585
TI **Enzyme replacement therapy** for Gaucher
disease.
AU Beutler E; Kay A; Saven A; Garver P; Thurston D; Dawson A; Rosenbloom B
CS Department of Molecular and Experimental Medicine, Research Institute of
Scripps Clinic, La Jolla, CA 92037.
NC DK36639 (NIDDK)
RR00833 (NCRR)
SO BLOOD, (1991 Sep 1) 78 (5) 1183-9.
Journal code: A8G; 7603509. ISSN: 0006-4971.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 199109
ED Entered STN: 19911020
Last Updated on STN: 20000303
Entered Medline: 19910927

23/45.
0A2356
1640